Exodos Life Sciences, based in Chapel Hill, North Carolina, is a privately held specialty pharmaceutical development company that focuses on advancing innovative drug concepts through the 505(b)(2) process to early clinical proof-of-principle, followed by asset (project) sale. We concentrate on applied therapy directed towards safe and effective topically delivered medications for the treatment of different human conditions including but not limited to pain and inflammation. Our medications greatly enhance the permeation of selective agents across human skin.
Exodos Life Sciences has adopted a semi-virtual model to control costs and advance drug development projects by utilizing its experienced business and medical research teams and on-call external pharmaceutical experts and partners. This allows management to precisely tailor medication project needs with the right level of pharmaceutical expertise and/or with key scientific opinion leaders with influence at the US Food and Drug Administration (FDA), academic medical centers and at the level of the payer (insurance company/government).
Our strategy is to establish a clinical stage drug development pipeline that addresses a significant unmet medical need and to move rapidly to proof-of-concept. The state-of-the-art biochemical research laboratory of Exodos Life Sciences is based in California.